Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncologyG Grazia, F. Schettini, Rodrigo Sánchez-Bayona et al.|npj Breast Cancer|2026Cited by 6
Supplementary Data 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast CancerEsther Sanfeliu, A. Prat, Anabel Martínez-Romero et al.|Unknown|2026Cited by 0
Figure 4 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast CancerEsther Sanfeliu, A. Prat, Anabel Martínez-Romero et al.|Unknown|2026Cited by 0
Figure 3 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast CancerEsther Sanfeliu, A. Prat, Anabel Martínez-Romero et al.|Unknown|2026Cited by 0
Figure 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast CancerEsther Sanfeliu, A. Prat, Anabel Martínez-Romero et al.|Unknown|2026Cited by 0